H E A L T H I N S I G H T S others . This process takes a tremendous amount of time and resources , from strategy development and market research to agency engagement , content creation and material development . Much like in the research and protocol writing processes , a lot of the steps in this part of the process could be automated with Generative AI .
For instance , when the drug is close to gaining approval , Generative AI could support commercial teams ’ research and compile strategy documents for secondary markets , taking into account specific regulations the therapy will need to adhere to in the new country .
Similarly , Generative AI can be used to adapt existing content – including website copy , brochures and other promotional materials – to the language and culture of the secondary market . This could shave up to a year off the go-to-market timeline in new countries and massively reduce marketing and design costs .
Taking the first steps
Introducing Generative AI into a business should be done one step at a time . It starts with fostering a culture of AI literacy , where every employee understands how the technology can be used to reshape and empower their role . It is also important to build a solid ecosystem of partners , which includes relationships with academic institutions , data providers , and specialty Generative AI vendors that will support the business ’ knowledge growth and internal capabilities .
Once Generative AI is introduced , it is a good idea to establish a body within the business to supervise how the organisation uses the technology and manages the upskilling and development of employees engaging with the tech . This body should also establish best practices and develop frameworks that guide the deployment of Generative AI across the business .
A life-saving revolution
Introducing Generative AI into a pharmaceutical business is no mean feat and is understandably very daunting . It is , however , essential for companies that want to stay ahead of their competitors and the market to invest in Generative AI . Likewise , it is crucial to ensure employees are provided training on how to best optimise the technology and create a body that supervises how the technology is being deployed across the business to avoid any misuse .
As companies continue to experiment with Generative AI across its various use cases , they will begin to lay the foundation needed to harness the full potential of this transformative technology , discovering , testing and bringing their drugs to market sooner . This improves patient outcomes due to safer , more effective and affordable drug development and increases revenue opportunities in a highly competitive market , driving value and improving patient outcomes at the same time . �
Bryan Hill , Chief Technology Officer , Life Sciences , Cognizant
www . intelligenthealth . tech 19